Details van artikel 352 van 352 gevonden artikelen
13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab
Titel:
13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab
Auteur:
Sandborn, W.J. Vermeire, S. D'Haens, G. Colombel, J.F. Fedorak, R.N. Spehlmann, M.E. Abreu, M.T. Mitchev, K. Jamoul, C. Rutgeerts, P.
Verschenen in:
Journal of Crohn's and colitis
Paginering:
Jaargang 3 () nr. 1 pagina's S8-S9
Jaar:
2009
Inhoud:
Uitgever:
European Crohn's and Colitis Organisation
Bronbestand:
Elektronische Wetenschappelijke Tijdschriften
Details van artikel 352 van 352 gevonden artikelen